Filtered By:
Specialty: Drugs & Pharmacology
Condition: Fatty Liver Disease (FLD)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
Non-alcoholic fatty liver disease (NAFLD) is a progressive metabolic disease characterized by hepatic steatosis, inflammation, and fibrosis that seriously endangers global public health. Epidemiological studies have shown that the incidence of non-alcoholic fatty liver disease in postmenopausal women has significantly increased. Studies have shown that estrogen deficiency is the main reason for this situation, and supplementing estrogen has become a new direction for preventing the occurrence of postmenopausal fatty liver. However, although classical estrogen replacement therapy can reduce the incidence of postmenopausal N...
Source: Frontiers in Pharmacology - August 30, 2023 Category: Drugs & Pharmacology Source Type: research

A network-based approach for isolating the chronic inflammation gene signatures underlying complex diseases towards finding new treatment opportunities
Complex diseases are associated with a wide range of cellular, physiological, and clinical phenotypes. To advance our understanding of disease mechanisms and our ability to treat these diseases, it is critical to delineate the molecular basis and therapeutic avenues of specific disease phenotypes, especially those that are associated with multiple diseases. Inflammatory processes constitute one such prominent phenotype, being involved in a wide range of health problems including ischemic heart disease, stroke, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, and autoimmune and neurodege...
Source: Frontiers in Pharmacology - October 12, 2022 Category: Drugs & Pharmacology Source Type: research

Suppression of nitric oxide synthase aggravates non-alcoholic steatohepatitis and atherosclerosis in SHRSP5/Dmcr rat via acceleration of abnormal lipid metabolism
CONCLUSIONS: NOS inhibition simultaneously aggravates NASH and atherosclerosis via hepatic lipid and cholesterol metabolism.PMID:35819592 | DOI:10.1007/s43440-022-00380-1
Source: Pharmacological Reports - July 12, 2022 Category: Drugs & Pharmacology Authors: Ikumi Sato Shusei Yamamoto Mai Kakimoto Moe Fujii Koki Honma Shota Kumazaki Mami Matsui Hinako Nakayama Sora Kirihara Shang Ran Shinichi Usui Ryoko Shinohata Kazuya Kitamori Satoshi Hirohata Shogo Watanabe Source Type: research

Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury
Biomed Pharmacother. 2021 Feb 27;138:111441. doi: 10.1016/j.biopha.2021.111441. Online ahead of print.ABSTRACTMetabolic syndrome (MetS) is a complex, multifactorial disease which lead to an increased risk of cardiovascular disease, type 2 diabetes, and stroke. However, selective, and potent drugs for the treatment of MetS are still lacking. Previous studies have found that Akebia saponin D (ASD) has beneficial effects on metabolic diseases such as obesity, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). Therefore, our study was designed to determine the effect and mechanism of action of ASD against MetS in ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 2, 2021 Category: Drugs & Pharmacology Authors: Song Yang Ting Hu He Liu Ya-Li Lv Wen Zhang Han Li Lingling Xuan Li-Li Gong Li-Hong Liu Source Type: research

Serum uric acid and diabetes: from pathophysiology to cardiovascular disease.
Abstract Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. In this narrative review, we consider the associations between hyperuricemia, hyperglycemia, atherosclerosis and thrombosis. Furthermore, we comment on the available evidence linking elevated SUA levels with the incidence and outcomes of coronary heart disease, stroke, per...
Source: Current Pharmaceutical Design - January 4, 2021 Category: Drugs & Pharmacology Authors: Katsiki N, Dimitriadis GD, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg-1·d-1) or atorvastatin calcium (AT, 10 mg kg-1·d-1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphoryl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 14, 2020 Category: Drugs & Pharmacology Authors: Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B Tags: Biomed Pharmacother Source Type: research

Iridoids of Valeriana fauriei contribute to alleviating hepatic steatosis in obese mice by lipophagy
Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Da-Hye Lee, So-Hyun Park, Yang Hoon Huh, Min Jung Kim, Hyo-Deok Seo, Tae-Youl Ha, Jiyun Ahn, Young-Jin Jang, Chang Hwa JungAbstractNonalcoholic fatty liver disease (NAFLD) is a common risk factor for metabolic syndrome that increases the risk of future cardiovascular disease, stroke, and diabetes. Recently, autophagy has been proposed as a means to prevent NAFLD. We investigated whether substances with autophagy-inducing activity alleviate NAFLD. The Valeriana fauriei (V. fauriei) was selected as a potential autophagy inducer among variou...
Source: Biomedicine and Pharmacotherapy - February 12, 2020 Category: Drugs & Pharmacology Source Type: research

Iridoids of Valeriana fauriei contribute to alleviating hepatic steatosis in obese mice by lipophagy.
Abstract Nonalcoholic fatty liver disease (NAFLD) is a common risk factor for metabolic syndrome that increases the risk of future cardiovascular disease, stroke, and diabetes. Recently, autophagy has been proposed as a means to prevent NAFLD. We investigated whether substances with autophagy-inducing activity alleviate NAFLD. The Valeriana fauriei (V. fauriei) was selected as a potential autophagy inducer among various natural materials using a Cyto-ID autophagy detection kit. V. fauriei 70 % ethanol extract (VFE) increased LC3II levels in the presence of the lysosomal inhibitor and reduced the GFP/mCherry puncta...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 9, 2020 Category: Drugs & Pharmacology Authors: Lee DH, Park SH, Huh YH, Jung Kim M, Seo HD, Ha TY, Ahn J, Jang YJ, Jung CH Tags: Biomed Pharmacother Source Type: research

Associations between Lifestyle-Related Diseases and Transporters Involved in Intestinal Absorption and Biliary Excretion of Cholesterol.
Abstract Westernization of dietary habits leads to an increase in lipid intake and is thought to be responsible for an increase in patients with dyslipidemia. It is a well-known fact that the impaired cholesterol homeostasis is closely related to the development of various lifestyle-related diseases such as fatty liver, diabetes, and gallstone as well as dyslipidemia leading to atherosclerosis and cardiovascular diseases such as heart attack and stroke. Therefore, appropriate management of cholesterol levels in the body is considered important in prevention and treatments of these lifestyle-related diseases and in...
Source: Biological and Pharmaceutical Bulletin - January 11, 2018 Category: Drugs & Pharmacology Authors: Yamanashi Y, Takada T, Suzuki H Tags: Biol Pharm Bull Source Type: research

Carthami flos: a review of its ethnopharmacology, pharmacology and clinical applications
ABSTRACTCarthami flos, the dried floret of Carthamus tinctorius L., Asteraceae (safflower), has been widely used in traditional Chinese medicine to treat a broad range of ailments, such as coronary heart disease, angina pectoris, gynecologic disease, stroke, and hypertension. However, although several studies on Carthami flos have been done consecutively, the results are usually scattered across various documents. This review aims to provide up-to-date information on the traditional uses, pharmacology, clinical applications, and toxicology of Carthami flos in China and thereby to provide a basis for further investigation o...
Source: Revista Brasileira de Farmacognosia - November 17, 2015 Category: Drugs & Pharmacology Source Type: research